查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495976

全球神經假體市場 - 2024 年至 2029 年預測

Global Neuroprosthetics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年神經修復市場價值為40.52億美元，預計複合年成長率為12.36%，到2029年市場規模將達到91.24億美元。

神經假體是植入神經損傷患者體內以補充和恢復神經正常功能，從而幫助部分恢復正常身體功能的裝置。全球神經病變的增加是預計在預測期內推動神經修復市場成長的關鍵因素之一。該市場包括腦機介面、脊髓刺激設備、人工電子耳、深層腦部刺激器和視網膜植入等各種類型的設備。主要參與企業包括成熟的醫療設備公司和新興新興企業。

FDA 和 EMA 等衛生當局的監管核准保證了安全性和有效性。技術挑戰包括複雜神經網路設備的開發、倫理考量、隱私問題和社會接受度。此外，隨著糖尿病患者數量的增加，許多人正遭受神經損傷，預計未來幾年對神經假體的需求將迅速增加。此外，多年來聽力損失人數大幅增加，預計未來幾年將大幅增加，進一步促進評估期間神經修復市場的成長。

市場促進因素：

  • 由於神經系統疾病的增加，神經假體市場預計將擴大。

全球患有神經病變的人數正在增加，這是預計在預測期內推動神經假體需求的主要原因之一。根據世界衛生組織 (WHO) 的數據，過去 30 年來，神經病變導致的死亡人數增加了近 39%。此外，神經病變患者的數量正在逐年增加，由於老年人口的增加、兒童死亡率的下降以及生存率和平均壽命的增加，預計未來該數字將進一步增加。

根據泛美衛生組織（PAHO）的資料，巴西每10萬人的殘障壽命（YLD）從2010年的784.06年增加到2019年的813.74年。在墨西哥，這數字從2010年的721.78增加到2019年的737.02。在美國，神經系統疾病死亡人數從2010年的每10萬人39.29人增加到2019年的47.39人，增加超過20%。

此外，阿茲海默症、失智症和帕金森氏症等疾病是成長最快的神經系統疾病。例如，根據泛美衛生組織的數據，加拿大每10萬人的傷殘調整生命年（DALY）從2010年的351.30躍升至2019年的415.70，成長超過18%。

  • 聽力損失的日益普遍可能會導致對義肢假體的需求激增。

由於神經助聽器用於治療嚴重聽力損失，全球聽力損失盛行率的不斷上升是預計未來幾年促進神經修復市場成長的關鍵因素。根據世界衛生組織的資料，巴西聽力損失的絕對人數從2008年的1000萬增加到2018年的1300萬。

在中國，聽力損失人數從2008年的7400萬增加到2018年的9600萬，在印度，這一數字從2008年的7650萬增加到2018年的1億。世界衛生組織預測，聽力損失人數將從2020年的4.3億增加到2050年的7億人以上。預計這將導致對義肢假體的需求大幅增加。

預計亞太地區將佔據主要市場佔有率。

從地理上看，由於該地區神經病變病例數量不斷增加，預計亞太地區將佔據重要的市場佔有率。此外，高品質的醫療保健系統和容易接觸到患者，使診斷和治療更加有力，也是該地區神經修復術市場規模巨大的重要原因。由於聽力損失盛行率上升，亞太地區預計將顯著成長。

此外，根據世界衛生組織的資料，南亞殘疾性聽力損失的絕對人數將從2018年的1.31億增加到2030年的1.76億，並預計在2050年進一步增加到2.67億。此外，由於該地區糖尿病患者數量迅速增加，導致大量患者神經和血管受損，預計評估期間亞太地區對義肢假體的需求將進一步激增。

主要發展

  • 2024 年 1 月 - 萊斯大學和休士頓衛理公會大學建立神經系統復原中心 (CNSR)，這是一個神經科學研究和治療創新的跨學科合作中心。該中心旨在透過匯集科學家、臨床醫生、工程師和外科醫生來改善神經護理，以解決中風恢復和脊髓損傷等醫療挑戰。重點關注領域包括腦功能恢復、輕度創傷性腦損傷檢測、運動功能恢復、平衡和生物回饋療法訓練。
  • 2023 年 3 月 - 全球植入式聽力解決方案領導者 Cochlear 成為首家獲得 ISO/IEC 27001資訊安全管理認證的聽力植入製造商。此認證評估資料保護並表明科利耳對全球最佳實踐的承諾。該認證還認可了科利耳在數位產品方面的高標準，包括連網型護理，透過智慧應用程式和軟體解決方案提供便利的護理選擇，提高外科醫生對佩戴的信心，並最佳化術後臨床表現，這表明了其承諾。
  • 2022 年 12 月 -薩斯喀徹爾省政府、衛生署和薩斯喀徹爾衛生局 (SHA) 啟動了擴展人工植入計劃，以幫助需要更換外部聲音處理器的嚴重聽力損失人士。根據該計劃，您為每個處理器自付費用 840 美元，衛生署承擔剩餘費用（通常在 8,000 美元至 12,000 美元之間）。該計劃將在接下來的幾個月內覆蓋約 70 個聲音處理器，此後每年覆蓋 50 個。預計2022-23年耗資44.6萬美元，每年耗資30萬美元。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球神經義肢市場：依類型

  • 介紹
  • 輸出神經假體
  • 輸入神經假體

第6章 全球神經義肢市場：依技術分類

  • 介紹
  • 腦深部電刺激療法
  • 脊髓刺激
  • 薦椎神經刺激
  • 經顱磁刺激
  • 迷走神經刺激

第7章 全球神經義肢市場：依應用分類

  • 介紹
  • 聽覺處理障礙
  • 帕金森氏症
  • 癲癇
  • 眼科疾病
  • 循環系統疾病
  • 麻痺
  • 阿茲海默症
  • 其他

第8章全球神經義肢市場：依地區分類

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • SenArs
  • LivaNova PLC
  • Medtronic PLC
  • Sonova Holding AG
  • Boston Scientific Corporation
  • Cochlear Ltd
  • Demant AS
  • Abbott Laboratories
  • NeuroPace, Inc.
  • BrainGate
  • NDI Medical
簡介目錄
Product Code: KSI061612097

The global neuroprosthetics market is evaluated at US$4.052 billion for the year 2022 and is projected to grow at a CAGR of 12.36% to reach the market size of US$9.124 billion by 2029.

Neuroprosthetics are devices implanted in patients with neural damage to compensate for and restore the normal functioning of the nerves, which consequently help in partially restoring normal bodily functions. The rising incidences of neurological disorders worldwide are one of the major factors anticipated to boost the global neuroprosthetics market growth during the forecast period. The market includes various types of devices, such as brain-machine interfaces, spinal cord stimulators, cochlear implants, deep brain stimulators, and retinal implants. Key players include established medical device companies and emerging startups.

Regulatory approvals from health authorities like the FDA and EMA ensure safety and efficacy. Technological challenges include developing devices for complex neural networks, ethical considerations, privacy issues, and societal acceptance. Furthermore, the growing number of diabetes patients, leading to nerve damage in many people, is also expected to lead to a surge in demand for neuroprosthetics in the coming years. Moreover, the number of people with disabling hearing loss has been increasing substantially over the years, and its projected rapid rise in the coming years is further anticipated to augment the global neuroprosthetics market growth during the assessment period.

Market Drivers:

  • Rising cases of neurological disorders are expected to increase the global neuroprosthetics market.

The number of people suffering from neurological disorders is on the rise worldwide and is one of the prominent reasons anticipated to drive the demand for neuroprosthetics during the forecast period. According to the World Health Organization, the number of deaths caused by neurological disorders has increased by nearly 39% in the last 30 years. It has also been stated that an increase in the number of patients with neurological disorders has been seen over the years, while the number of cases is further projected to grow in the coming years owing to a growing elderly population, a decrease in child mortality, and rise in the survival rate and life expectancy.

As per data from the Pan America Health Organization (PAHO), the years lived with disability (YLDs) per 100,000 population in Brazil increased from 784.06 years in 2010 to 813.74 years in 2019. In Mexico, it increased from 721.78 years in 2010 to 737.02 years in 2019. In the United States, the deaths from neurological disorders increased from 39.29 deaths per 100,000 population in 2010 to 47.39 deaths in 2019, witnessing an increase of more than 20%.

Furthermore, diseases such as Alzheimer's, dementia, and Parkinson's disease are some of the neurological disorders spreading fast. For instance, according to PAHO, Canada has witnessed a surge in disability-adjusted life years (DALYs) per 100,000 population from 351.30 in 2010 to 415.70 in 2019, growing by more than 18%.

  • The growing prevalence of hearing loss would lead to a surge in neuroprosthetics demand.

As neuroprosthetics are used in severe hearing loss, the increasing prevalence of hearing loss worldwide is a significant factor expected to augment the global neuroprosthetics market growth in the coming years. According to data from the WHO, the absolute number of people with hearing loss in Brazil has increased from 10 million in 2008 to 13 million in 2018.

In China, the number of people with hearing loss increased from 74 million in 2008 to 96 million in 2018, while in India, this number increased from 76.5 million in 2008 to 100 million in 2018. WHO has projected that people with disabling hearing loss will increase from 430 million in 2020 to more than 700 million by 2050. This is expected to surge the demand for neuroprosthetics significantly.

Asia Pacific region is projected to have a major market share.

Geographically, the Asia Pacific region is anticipated to hold a significant market share owing to the rising cases of neurological disorders in the region. Furthermore, the presence of a quality healthcare system and its accessibility to patients make diagnosis and treatment stronger, which is another prominent reason for the large market size of neuroprosthetics in the region. The Asia Pacific region is anticipated to witness substantial growth due to the rising prevalence of hearing loss in the region.

Additionally, according to data from the WHO, the absolute number of people with disabling hearing loss in South Asia is projected to increase from 131 million in 2018 to 176 million in 2030 and further to 267 million in 2050. Furthermore, the rapidly growing cases of diabetes in the region are leading to damage to the nerves and blood vessels of a large number of patients, which is further projected to surge the demand for neuroprosthetics in the Asia Pacific region during the assessment period.

Key Developments:

  • January 2024- Rice University and Houston Methodist established the Center for Neural Systems Restoration (CNSR), a joint interdisciplinary center for neuroscience research and treatment innovation. The center aims to improve neurological care by bringing together scientists, clinicians, engineers, and surgeons to tackle medical challenges like stroke recovery and spinal cord injury. Key focus areas include brain function restoration, mild traumatic brain injury detection, mobility restoration, balance, and biofeedback training. The Houston Methodist facility included operating rooms, a laboratory for diagnosis and assessment, device fabrication and testing, and education and training opportunities.
  • March 2023- Cochlear, a global leader in implantable hearing solutions, become the first hearing implant manufacturer to receive ISO/IEC 27001 certification for information security management. This certification assesses data protection and demonstrates Cochlear's commitment to global best practices. The certification also signifies Cochlear's commitment to high standards in digital products, such as its Connected Care, which offers convenient care options through Smart Apps and software solutions, enhancing surgeons' confidence in device placement and optimizing postoperative clinical performance.
  • December 2022- The Saskatchewan Government, the Ministry of Health, and the Saskatchewan Health Authority (SHA) launched an expanded Cochlear Implant Program to assist individuals with severe hearing loss who need their external sound processor replaced. The program allows individuals to co-pay $840 per processor, with the Ministry of Health covering the remaining cost, typically $8,000 to $12,000. The program covers approximately 70 sound processors in the next few months and 50 devices per year thereafter. The program is expected to cost $446,000 in 2022-23, with an annual cost of $300,000.

Market Segmentation:

By Type

  • Output Neural Prosthetics
  • Input Neural Prosthetics

By Technique

  • Deep Brain Stimulation
  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation
  • Transcranial Magnetic Stimulation
  • Vague Nerve Stimulation

By Application

  • Auditory Processing Disorders
  • Parkison's Disease
  • Epilepsy
  • Ophthalmic Disease
  • Cardiovascular Disease
  • Paralysis
  • Alzheimer's Disease
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL NEUROPROSTHETICS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Output Neural Prosthetics
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Input Neural Prosthetics
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL NEUROPROSTHETICS MARKET BY TECHNIQUE

  • 6.1. Introduction
  • 6.2. Deep Brain Stimulation
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Spinal Cord Stimulation
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Sacral Nerve Stimulation
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Transcranial Magnetic Stimulation
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Vague Nerve Stimulation
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL NEUROPROSTHETICS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Auditory Processing Disorders
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Parkison's Disease
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Epilepsy
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Ophthalmic Disease
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Cardiovascular Disease
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness
  • 7.7. Paralysis
    • 7.7.1. Market Opportunities and Trends
    • 7.7.2. Growth Prospects
    • 7.7.3. Geographic Lucrativeness
  • 7.8. Alzheimer's Disease
    • 7.8.1. Market Opportunities and Trends
    • 7.8.2. Growth Prospects
    • 7.8.3. Geographic Lucrativeness
  • 7.9. Others
    • 7.9.1. Market Opportunities and Trends
    • 7.9.2. Growth Prospects
    • 7.9.3. Geographic Lucrativeness

8. GLOBAL NEUROPROSTHETICS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Technique
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Technique
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Technique
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Technique
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Technique
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. SenArs
  • 10.2. LivaNova PLC
  • 10.3. Medtronic PLC
  • 10.4. Sonova Holding AG
  • 10.5. Boston Scientific Corporation
  • 10.6. Cochlear Ltd
  • 10.7. Demant AS
  • 10.8. Abbott Laboratories
  • 10.9. NeuroPace, Inc.
  • 10.10. BrainGate
  • 10.11. NDI Medical